Tendon mechanisms and translational research · Review · 2013
Does shockwave help jumper's knee (kneecap tendon pain)?
This review looked at four small trials of focused shockwave for jumper's knee. Three reported bigger gains in knee scores with shockwave. In the largest trial, which used a placebo comparison, gains were about the same in both groups.
- trials, with 171 people
- 4
- sessions, depending on the trial
- 1–5
- weeks of follow-up in the three placebo-controlled trials
- 12–22
Good to know: Four trials with 171 people. The biggest gain came from the one trial without a placebo group.
van der Worp H, van den Akker-Scheek I, van Schie H, et al. Knee Surgery, Sports Traumatology, Arthroscopy : Official Journal of the ESSKA, 2013 · Read the paper ↗
How this study worked
Conceptual animation: a focused front converges, then spreads. Not to scale. Tap the field to send a pulse.
What the trials used
- Device modality
- All four trials used focused ESWT: electromagnetic (two), electrohydraulic (one) or piezoelectric (one).
- Session and pulse parameters
- Protocols ranged from one to five sessions and 1,000–2,000 impulses; energy flux densities ranged from 0.17–0.25 mJ/mm² where reported.
- Co-intervention and comparator
- Three trials used placebo ESWT; one used conservative care. Decline-squat training was included with both arms in Peers et al.; Wang et al. control included NSAIDs, physiotherapy, exercise, knee strap and activity modification.
Who took part
171 people with jumper's knee (patellar tendinopathy) in four trials; 89 had shockwave.
Side effects
The review did not report side effects for these four trials.
All the numbers and the full appraisal
Every reported result
The results, in numbers.
Patients with patellar tendinopathy in four RCTs; the review table reports study totals of 40, 19, 50 (with paired tendon count also given) and 62 participants, alongside ESWT group counts. The rest of the review includes mechanistic literature.
Table 1 reports number analyzed in the arm; do not treat these trial counts as one cohort.
Table 1 reports number analyzed in the arm; do not treat these trial counts as one cohort.
Table 1 reports number analyzed in the arm; do not treat these trial counts as one cohort.
Table 1 reports number analyzed in the arm; do not treat these trial counts as one cohort.
Table reports 27 patients and 30 treated tendons; counts are participants.
Table 1 reports number analyzed in the arm; do not treat these trial counts as one cohort.
Table 1 reports number analyzed in the arm; do not treat these trial counts as one cohort.
Table 1 reports number analyzed in the arm; do not treat these trial counts as one cohort.
VISA-P improvement, Peers trial4 reported outcomes
VISA-P improvement, Peers trial
Victorian Institute of Sport Assessment–Patella (VISA-P) Points difference versus control
ESWT versus trial control; source table labels this as improvement compared with control
1 study · 40 participants in this estimate
The review table marks a significant difference; it does not report its p value or CI.
Analysis details and source
Table 1 gives this VISA-P value as improvement compared with control; it does not state the estimate type or uncertainty.
VISA-P improvement, Taunton et al. trial
Victorian Institute of Sport Assessment–Patella (VISA-P) Points difference versus control
ESWT versus trial control; source table labels this as improvement compared with control
1 study · 19 participants in this estimate
The review table marks a significant difference; it does not report its p value or CI.
Analysis details and source
Table 1 gives this VISA-P value as improvement compared with control; it does not state the estimate type or uncertainty.
VISA-P improvement, Wang et al. trial
Victorian Institute of Sport Assessment–Patella (VISA-P) Points difference versus control
ESWT versus trial control; source table labels this as improvement compared with control
1 study
The review table marks a significant difference; it does not report its p value or CI.
Analysis details and source
Table 1 reports total n=50 / ESWT n=27 and separately total 54 tendons / ESWT 30 tendons; control-arm denominator and uncertainty are not reported in that row.
VISA-P improvement, Zwerver et al. trial
Victorian Institute of Sport Assessment–Patella (VISA-P) Points difference versus control
ESWT versus trial control; source table labels this as improvement compared with control
1 study · 62 participants in this estimate
The review table marks no significant difference; this does not establish equivalence.
Analysis details and source
Table 1 gives this VISA-P value as improvement compared with control; it does not state the estimate type or uncertainty.
How treatment was delivered
All four trials used focused ESWT: electromagnetic (two), electrohydraulic (one) or piezoelectric (one).
Protocols ranged from one to five sessions and 1,000–2,000 impulses; energy flux densities ranged from 0.17–0.25 mJ/mm² where reported.
Three trials used placebo ESWT; one used conservative care. Decline-squat training was included with both arms in Peers et al.; Wang et al. control included NSAIDs, physiotherapy, exercise, knee strap and activity modification.
The review table and narrative do not provide adverse-event results for these four RCTs.
Four RCTs differed in protocols, controls and follow-up. PEDro scores were 8, 4, 5 and 9; the largest apparent effect was in the only study without placebo.
Table 1 gives VISA-P improvement differences and a yes/no significance label but omits p values and confidence intervals. Wang et al. reports paired participant/tendon counts; unit handling is unclear in the summary table.
Findings checked against the full source by a separate automated reviewer.
Limitations noted by the reviewers
- Four RCTs differed in protocols, controls and follow-up. PEDro scores were 8, 4, 5 and 9; the largest apparent effect was in the only study without placebo.
- Table 1 gives VISA-P improvement differences and a yes/no significance label but omits p values and confidence intervals. Wang et al. reports paired participant/tendon counts; unit handling is unclear in the summary table.
Source-linked critical reading
Narrative technology review with a systematic clinical component
Technical source record
Full-text XML read: article body, Table 1 (four RCTs), Table 2, Figures 1–3 captions, discussion and end-matter.
This review found mixed evidence for shockwave treatment of patellar tendinopathy. The apparent benefit varied across small trials and cannot establish a reliable chance of improvement or a best device or dose.
How do focused and radial shockwave technologies differ, and what does the evidence show for patellar tendinopathy?
Narrative technology and mechanism review with a focused systematic search and quality appraisal of four RCTs in patellar tendinopathy.
Four trials enrolled patients with patellar tendinopathy; the review table reports 171 patients in the analyses, 89 of them in ESWT groups (one trial counts 50 patients, 27 with ESWT, and 54 tendons, 30 treated with ESWT).
The four trials used focused ESWT generated by electromagnetic, electrohydraulic or piezoelectric devices; impulse counts, energy-flux density, number of sessions and co-interventions varied.
Three trials used placebo ESWT; one compared treatment with conservative care. Decline-squat training accompanied both active and placebo arms in one study.
The review table reports between-group VISA-P improvement differences of 17.4, 3.7, 47.6 and 0.7 points; three were labelled statistically significant and one was not. The review does not provide uncertainty intervals or p values for these table entries.
Evidence was conflicting. The largest improvement came from the only study without a placebo intervention; the higher-quality placebo-controlled study reported no significant difference.
The review does not synthesize adverse events for the four trials in its table.
Only four RCTs were found; diagnostic criteria, disease stage, generators, dose settings and follow-up varied. PEDro scores ranged from 4 to 9. Table-reported VISA-P differences lack CIs and p values, limiting assessment of precision.
The article is a dated 2012 review and does not establish current comparative effectiveness. Findings for patellar tendinopathy cannot automatically be generalized to other tendons or to a specific contemporary device.
Trials should use consistent diagnosis and tendinopathy-stage criteria, prespecify device and dose parameters, include credible sham controls, and report complete between-group estimates with uncertainty and harms.
Read the original article.
ESWT for tendinopathy: technology and clinical implications.
van der Worp H, van den Akker-Scheek I, van Schie H, Zwerver J. · Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA · 2013
Open the publication record or available full-text files.
Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →